These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16517279)

  • 1. Digitalis intoxication induced by paroxetine co-administration.
    Yasui-Furukori N; Kaneko S
    Lancet; 2006 Mar; 367(9512):788. PubMed ID: 16517279
    [No Abstract]   [Full Text] [Related]  

  • 2. Delirium and multiple electrolyte abnormalities associated with high dose paroxetine exposure.
    Chuang YF; Chiu YL; Hwang TJ; Chu TS
    Psychiatry Clin Neurosci; 2006 Oct; 60(5):642-3. PubMed ID: 16958954
    [No Abstract]   [Full Text] [Related]  

  • 3. Delirium induced by abrupt discontinuation of paroxetine.
    Hayakawa Y; Sekine A; Shimizu T
    J Neuropsychiatry Clin Neurosci; 2004; 16(1):119-20. PubMed ID: 14990771
    [No Abstract]   [Full Text] [Related]  

  • 4. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
    Hori H; Yoshimura R; Ueda N; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
    World J Biol Psychiatry; 2009; 10(4 Pt 2):620-2. PubMed ID: 18609433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible paroxetine-induced symptomatic hypothyroidism.
    Takahashi M; Sawayama E; Sawayama T; Miyaoka H
    Pharmacopsychiatry; 2007 Sep; 40(5):201-2. PubMed ID: 17874352
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison study of venlafaxine and paroxetine for the treatment of depression in elderly Chinese inpatients.
    Hwang JP; Yang CH; Tsai SJ
    Int J Geriatr Psychiatry; 2004 Feb; 19(2):189-90. PubMed ID: 14758586
    [No Abstract]   [Full Text] [Related]  

  • 7. Visual and auditory hallucinations during normal use of paroxetine for treatment of major depressive disorder.
    Monji A; Kato T; Mizoguchi Y; Horikawa H; Seki Y; Kanba S
    J Neuropsychiatry Clin Neurosci; 2011; 23(4):E14-5. PubMed ID: 22231326
    [No Abstract]   [Full Text] [Related]  

  • 8. Hallucination induced by paroxetine discontinuation in patients with major depressive disorders.
    Yasui-Furukori N; Kaneko S
    Psychiatry Clin Neurosci; 2011 Jun; 65(4):384-5. PubMed ID: 21489048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minor strokes related to paroxetine discontinuation in an elderly subject: emergent adverse events.
    Ramasubbu R
    Can J Psychiatry; 2003 May; 48(4):281-2. PubMed ID: 12776398
    [No Abstract]   [Full Text] [Related]  

  • 10. Odd odds.
    Andrade C
    J Clin Psychiatry; 2011 Nov; 72(11):1558-9; author reply 1559. PubMed ID: 22127198
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
    Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS
    Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevation of nortriptyline plasma levels after cotreatment with paroxetine and thioridazine.
    Ghaemi SN; Kirkwood CK
    J Clin Psychopharmacol; 1998 Aug; 18(4):342-3. PubMed ID: 9690702
    [No Abstract]   [Full Text] [Related]  

  • 13. Depression and psoriasis comorbidity. Treatment with paroxetine: two case reports.
    Luis Blay S
    Ann Clin Psychiatry; 2006; 18(4):271-2. PubMed ID: 17162628
    [No Abstract]   [Full Text] [Related]  

  • 14. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
    Greist J; McNamara RK; Mallinckrodt CH; Rayamajhi JN; Raskin J
    Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specificity profile of paroxetine in major depressive disorder: meta-regression of double-blind, randomized clinical trials.
    Serretti A; Gibiino S; Drago A
    J Affect Disord; 2011 Jul; 132(1-2):14-25. PubMed ID: 20863574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rising digoxin serum levels and intoxication despite digoxin withdrawal in an elderly patient: a case report.
    Peeters P; Vandergoten P; Lambert M; Mets T
    Acta Clin Belg; 2002; 57(5):250-3. PubMed ID: 12534131
    [No Abstract]   [Full Text] [Related]  

  • 17. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials.
    Carpenter DJ; Fong R; Kraus JE; Davies JT; Moore C; Thase ME
    J Clin Psychiatry; 2011 Nov; 72(11):1503-14. PubMed ID: 21367354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study.
    Pae CU; Kim YJ; Won WY; Kim HJ; Lee S; Lee CU; Lee SJ; Kim DW; Lee C; Min WS; Kim CC; Paik IH; Serretti A
    Hum Psychopharmacol; 2004 Jan; 19(1):25-9. PubMed ID: 14716708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exacerbation of extrapyramidal symptoms with paroxetine.
    Arya DK; McKenzie J; Worrall N
    Aust N Z J Psychiatry; 1995 Sep; 29(3):521-2. PubMed ID: 8573063
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and tolerability of controlled-release paroxetine.
    Golden RN
    Psychopharmacol Bull; 2003; 37 Suppl 1():176-86. PubMed ID: 14566210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.